Moderna Shares Surge 120% After Melanoma Vaccine Trial Success
By United One News · AI-generated summary of 3 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
- Moderna’s stock jumped 120% on Thursday after its personalized mRNA melanoma vaccine, developed with Merck, achieved positive Phase 3 results.
- The trial’s success has raised expectations for a new cancer treatment and caused significant losses for short sellers, estimated at around $5 billion.
- The surge reflects investor optimism about the vaccine’s potential and the company’s expanding oncology portfolio.
“Moderna Shares Rocket 160% As Cancer Vaccine Trial Success Inflicts $5 Billion Loss On Short Sellers.”
Covered by 3 outlets across the spectrum: 0% left, 33% center, 67% right.
How each side framed it
Moderna stock jumps 120% after cancer vaccine trial win: What investors need to know
Moderna Shares Rocket 160% As Cancer Vaccine Trial Success Inflicts $5 Billion Loss On Short Sellers
Left-leaning outlets have under-covered this story. Of 3 outlets, only 0 are on the left of the spectrum.
Timeline
First reported by Hindustan Times on ; 3 articles from 3 outlets so far.
Who is covering this story
- Center (1): Hindustan Times
- Right-leaning (2): Sunday Guardian, Times Now
Sources
- Moderna stock jumps 120% after cancer vaccine trial win: What investors need to know — Hindustan Times (center) ·
- Moderna Shares Rocket 160% As Cancer Vaccine Trial Success Inflicts $5 Billion Loss On Short Sellers — Sunday Guardian (right-leaning) ·
- Merck’s ‘Made-For-You’ Cancer Vaccine Cuts Melanoma Recurrence: Could This Be The Future? — Times Now (right-leaning) ·